%0 Journal Article
%T Metastatic melanoma and vemurafenib: novel approaches
%A Ramon Andrade De Mello
%J Rare Tumors
%D 2012
%I PAGEPress Publications
%R 10.4081/rt.2012.e31
%X Metastatic melanoma (MM) presents a treatment challenge to oncologists worldwide. Dacarbazine is the first line chemotherapy treatment for MM, though the overall response rates are very poor. Recently, the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation was found to play a main role in MM. This mutation is present in 40-60% of melanoma patients. Vemurafenib is a BRAF kinase inhibitor that showed impressive results in phase I-III trials and was thus recently approved for the treatment of MM. This paper will briefly focus on vemurafenib in the treatment of MM and highlight concerns.
%K malignant melanoma
%K vemurafenib
%K BRAF
%K metastatic disease
%K skin cancer
%U http://www.pagepress.org/journals/index.php/rt/article/view/4100